• Tue, May 17, 2022
Matt Cross Maintained (SYRS) at Strong Buy with Decreased Target to $100 on, May 17th, 2022
Matt Cross of Alliance Global Partners, Maintained "Syros Pharmaceuticals, Inc." (SYRS) at Strong Buy with Decreased Target from $140 to $100 on, May 17th, 2022.
Matt, nor any peers, have made any analyst calls on SYRS in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30Like: 👍
